Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Bcr-abl tyrosine kinase inhibitors (Primary) ; Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 15 Nov 2019 Status changed from not yet recruiting to recruiting.
- 02 Oct 2019 Planned initiation date changed from 1 Jul 2019 to 1 Dec 2019.
- 02 May 2019 Planned initiation date changed from 1 May 2019 to 1 Jul 2019.